Dette er bekræftet i in vivo- forsøg med raske frivillige, som ikke viste interaktion mellem dabigatran og følgende aktive stoffer: atorvastatin (CYP3A4), digoxin (P- glykoprotein- transporterinteraktion) og diclofenac (CYP2C9).
This has been confirmed by in vivo studies with healthy volunteers, who did not show any interaction between this treatment and the following active substances: atorvastatin (CYP3A4), digoxin (P- glycoprotein transporter interaction) and diclofenac (CYP2C9).